13F Holdings
中文EN

ALLR Allarity Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1860657 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-2.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,938.3%
Net margin-4,493.7%
FCF margin-3,785.4%
EBITDA margin—

Returns

ROE-322.7%
ROA-65.5%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets108.3%
Debt / equity—
Current ratio0.91x
Interest coverage-6.83x

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue20.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$320,000$0———
Gross profit———-$2.27M—
R&D expense$6.60M$6.10M$7.10M$6.93M$14.20M
SG&A expense$6.32M$11.44M$10.03M$9.96M$12.36M
Operating income-$12.61M-$27.24M-$17.13M-$34.46M-$26.56M
Interest expense$185,000$653,000$498,000$223,000$99,000
Pretax income-$11.23M-$24.90M-$11.82M-$17.58M—
Income tax$0-$381,000$83,000-$1.52M$133,000
Net income-$11.23M-$24.52M-$11.90M-$16.06M-$26.65M
EBITDA—-$27.23M-$17.09M-$34.40M-$26.45M
EPS (basic)-0.78-15.65-6,031.31-3,093.42-4.19
EPS (diluted)——-10.26-3,093.42-4.19
Weighted avg. shares (diluted)——1.99M6,8056.36M
Banking
Net interest income————-$1.35M
Balance sheet
Cash & equivalents$14.69M$19.53M$166,000$2.03M$19.55M
Current assets$17.93M$22.34M$1.97M$4.97M$21.40M
PP&E, net$330,000$309,000$20,000$21,000$8,000
Intangibles—$0$9.87M$9.55M$28.14M
Total assets$18.26M$22.65M$11.86M$14.54M$49.63M
Current liabilities$8.43M$10.84M$14.17M$11.22M$20.72M
Short-term debt$0—$250,000——
Long-term debt——$2.69M$2.64M—
Total debt——$2.94M$2.64M—
Total liabilities$8.43M$10.84M$14.61M$12.65M$30.85M
Shareholders' equity$9.83M$11.81M-$2.75M-$113,000$18.15M
Net debt——$2.77M$615,000—
Shares outstanding16.08M7.30M9,81211,3568.10M
Cash flow statement
Operating cash flow-$14.82M-$17.35M-$12.74M-$16.82M-$14.89M
Capital expenditure$8,000$298,000$0$18,000—
Free cash flow-$14.83M-$17.65M-$12.74M-$16.84M—
Investing cash flow-$8,000-$298,000$0$791,000$1.00M
Financing cash flow$10.65M$36.79M$10.99M-$1.31M$33.82M
Depreciation & amortization—$9,000$37,000$60,000$106,000
Stock-based compensation$482,000$71,000-$71,000$1.75M$6.37M
Share buybacks$3.19M$0———

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.